MannKind Corp. (NASDAQ: MNKD) Starts Presentation at 29th Annual ROTH Conference
MannKind (NASDAQ: MNKD) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the United States. Its approved product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with Type 1 and Type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California. For more information, visit the company’s website at www.mannkindcorp.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and…







